Inventia Life Science
- Company typePrivate
- Founded2013
- HeadquartersAlexandria, Australia
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
Inventia Life Science firmographics
Firmographics- Name
- Inventia Life Science
- Legal name
- Inventia Life Science Pty Ltd
- Website
- https://inventialifescience.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Ownership category
- akta.pro rank
Inventia Life Science industry classification
Industry- Product category
- 3D Bioprinting Instruments
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Inventia Life Science is headquartered
LocationHeadquarters
- HQ city
- Alexandria
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Inventia Life Science business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- RASTRUM Platform Instruments (Hardware): Inventia Life Science sells the RASTRUM and RASTRUM Allegro 3D bioprinting instruments. These are capital equipment purchases with pricing based on configuration and throughput capabilities. The Allegro instrument targets high-throughput drug discovery and screening workflows.
- Consumables (Matrices, Reagents, PrintRun Kits): Recurring revenue from proprietary consumables including RASTRUM Matrices (tunable, xeno-free hydrogels), Cell Recovery Solution, and PrintRun kits. These are recurring purchases tied to instrument usage and experiment throughput.
- Discovery Services: Fee-for-service scientific engagements including model optimization, custom development projects, end-to-end 3D workflow development, high-throughput screening enablement, and scientific support/tech transfer. engagements are structured as project-based consulting, with options via platforms like Scientist.com and Science Exchange.
Go-to-market motion2 records
Distribution channels12 records
Marketing channels11 records
Inventia Life Science product offering
Product offeringCore offering
Inventia Life Science develops and sells the RASTRUM 3D cell culture platform, a drop-on-demand bioprinting system used by pharmaceutical, biotech, and academic research customers to create reproducible 3D cell models for drug discovery, cancer research, and disease modeling. The offering spans RASTRUM and RASTRUM Allegro instruments, RASTRUM Cloud no-code software, proprietary PEG-based xeno-free RASTRUM Matrices, pre-validated Cell Model Architectures and Validated Solutions, and recurring consumables (PrintRun kits, Cell Recovery Solution). The company also sells the LIGŌ precision biodelivery device for regenerative surgery applications and provides fee-for-service Discovery Services engagements.
Product overview
Inventia Life Science offers the RASTRUM platform—a comprehensive digital bioprinting ecosystem for scalable 3D cell model generation. The core portfolio includes two instruments (RASTRUM Allegro for high-throughput screening at 35+ plates/day and RASTRUM for general desktop use), supported by RASTRUM Cloud software for no-code experimental design. The platform is complemented by Cell Model Architectures (8 architecture types for imaging, screening, co-cultures) and Matrices (tunable xeno-free hydrogels). Workflow solutions include Discovery Mode for flexible development and Validated Solutions (PDAC, Fibroblast Activation) with predefined Protocol and Data Packs. Expert support is available through Discovery Services. The company also operates LIGŌ, a separate clinical biodelivery device for regenerative surgery, and maintains the RASTRUM 3D Cell Model Network for collaborative research.
Differentiator
Problem solved
Functional benefit
Brands
- RASTRUM: The RASTRUM platform is a 3D bioprinting system for creating reproducible 3D cell models for drug discovery, disease modeling, and biomedical research. Includes multiple product variants including RASTRUM Allegro for high-throughput applications.
- LIGŌ
- Inventia Skin
Products and services
- RASTRUM Platform
Quantifiable outcome
- 96-well plate printed in 6 minutes; 384-well plate printed in 9 minutes; 35+ plates per 8-hour day
- +5 more outcomes
Companies that use Inventia Life Science
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Inventia Life Science technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature7 records
Inventia Life Science partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core.
- MSD (Merck & Co., Inc.)coreInventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery. This is a strategic co-development partnership aimed at creating physiologically relevant 3D models to support MSD's drug discovery programs targeting Alzheimer's, Parkinson's, and other neurodegenerative diseases.
- LonzacoreLonza is an authorized partner providing primary human hepatocytes for use with the RASTRUM platform. Inventia Life Science is an authorized Lonza partner, combining RASTRUM's 3D bioprinting technology with Lonza's primary hepatocyte products to create advanced 3D liver models for drug discovery, hepatotoxicity testing, and DILI studies.
- NSW GovernmentcoreInventia Life Science secured NSW Government Jobs Plus support to build a brand-new manufacturing and R&D facility in Sydney, representing a significant government partnership to advance local manufacturing and research capabilities in 3D bioprinting.
- Peter MacCallum Cancer CentrecorePeter MacCallum Cancer Centre was the site of the world's first RASTRUM 3D bioprinter installation, forming a research partnership to accelerate cancer research using advanced 3D tumor models. This represents a leading academic cancer research institution adopting RASTRUM technology.
- I&L BiosystemscorePrimary European distribution partner for RASTRUM, reselling and distributing products across Austria, Belgium, Denmark, France, Germany, Netherlands, Ireland, Sweden, Switzerland, and the UK. I&L Biosystems is a specialist distributor for life science research products.
- Biotron Healthcare India PVT LTDcoreDistribution agreement for RASTRUM in India, enabling market access and sales support for Indian pharmaceutical and academic research customers.
- SCRUM Inc.coreDistribution agreement for RASTRUM in Japan, enabling local sales, support, and distribution of RASTRUM products to Japanese researchers and pharmaceutical companies.
- Handok BiotechcoreDistribution partner for RASTRUM in South Korea, providing local market access for 3D cell culture products in the Korean research and pharmaceutical market.
- Interprise BrazilcoreDistribution partner for RASTRUM in Brazil, covering sales and distribution to Brazilian academic and pharmaceutical research institutions.
- DMark BiosciencescoreDistribution partner for RASTRUM in Canada, providing local distribution and support for Canadian researchers.
- Palex MedicalcoreDistribution partner for RASTRUM in Spain and Portugal, serving the Iberian Peninsula research and pharmaceutical market.
- Integrated BiocoreDistribution partner for RASTRUM in Taiwan, providing local market access for Taiwanese researchers and pharma companies.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Inventia Life Science competitors and assessment
Company assessmentDirect peers
- Emulate: Emulate is a US organ-on-chip company commercializing the Liver-Chip, Brain-Chip, and other organoids-on-chip products for pharma preclinical decision-making. It competes directly with Inventia's RASTRUM platform for pharma discovery budget and serves overlapping customer use cases around human-relevant in vitro biology.
- Mimetas: Mimetas is a Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D cell culture and disease modeling for pharma drug discovery. It is a direct competitor selling reproducible 3D microfluidic models into the same biopharma procurement cycles as RASTRUM.
- CN Bio: CN Bio is a UK organ-on-chip / MPS company focused on liver and disease models for drug discovery and safety. It is a direct competitor in the human-relevant in vitro tools space, with overlapping customers and use cases around hepatotoxicity and disease modeling.
- Organovo: Organovo is a US pioneer in 3D bioprinting of human tissue for drug discovery and therapeutic applications. While smaller and more therapeutically oriented, it shares the bioprinting IP thesis and serves pharma/biotech customers interested in 3D tissue models.
- InSphero: InSphero is a Swiss 3D cell culture company specializing in organoid-based and spheroid-based models for drug discovery and toxicology, including liver and disease models. It is a direct peer addressing the same pharma pain points (reproducible human-relevant 3D biology) with a different technology foundation.
- Aspect Biosystems: Aspect Biosystems is a Canadian 3D bioprinting company developing microfluidic 3D cell culture platforms for drug discovery and tissue engineering. It directly competes with RASTRUM as a bioprinting-based, multi-well plate compatible 3D cell model platform targeting pharma customers.
Others
- Revvity (formerly PerkinElmer): Revvity is a large life science tools and analytics vendor whose PhenoVue Cell Painting Kit integrates with RASTRUM. It is a complementary/ecosystem partner rather than direct competitor, providing high-content imaging and phenotypic readouts on top of Inventia's 3D models.
Broad incumbents
- Corning Life Sciences: Corning is a broad-incumbent life science tools supplier with its Matrigel, spheroid microplates, and 3D cell culture consumables portfolio. While not a direct drop-on-demand bioprinting competitor, it competes for the same pharma 3D cell culture budget through consumables and is a major reference standard in adjacent workflows.
- BICO (CELLINK): BICO (formerly CELLINK) is a Swedish life-science tools conglomerate offering bioprinters, bioinks, consumables and a growing portfolio of 3D cell culture and organ-on-chip companies. It overlaps with RASTRUM as a broader-incumbent bioprinting and 3D cell culture vendor, though BICO is portfolio-led while Inventia is vertically focused.
Emerging players
- Lena Biosciences: Lena Biosciences is a smaller US 3D cell culture and bioprinting company developing organ-on-a-chip and 3D tissue models for drug discovery. It is a niche emerging player in the same 3D cell culture category as Inventia's RASTRUM, focused on specialty applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inventia Life Science social profiles
Digital presenceInventia Life Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inventia Life Science leadership team
Management profileNumber of profiles
Profiles4 records
Inventia Life Science funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inventia Life Science M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inventia Life Science
What does Inventia Life Science do?
Inventia Life Science develops and sells the RASTRUM 3D cell culture platform, a drop-on-demand bioprinting system used by pharmaceutical, biotech, and academic research customers to create reproducible 3D cell models for drug discovery, cancer research, and disease modeling. The offering spans RASTRUM and RASTRUM Allegro instruments, RASTRUM Cloud no-code software, proprietary PEG-based xeno-free RASTRUM Matrices, pre-validated Cell Model Architectures and Validated Solutions, and recurring consumables (PrintRun kits, Cell Recovery Solution). The company also sells the LIGŌ precision biodelivery device for regenerative surgery applications and provides fee-for-service Discovery Services engagements.
Is Inventia Life Science a public or private company?
Inventia Life Science is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inventia Life Science founded?
Inventia Life Science was founded in 2013.
Where is Inventia Life Science based?
Inventia Life Science is headquartered in Alexandria, Australia, in the Oceania region.
How does Inventia Life Science make money?
Three revenue lines are on record. RASTRUM Platform Instruments (Hardware) is the primary driver. The others are consumables (Matrices, Reagents, PrintRun Kits) and discovery Services.
Who are Inventia Life Science's main competitors?
Direct peers on record are Emulate, Mimetas, CN Bio, Organovo, InSphero and Aspect Biosystems. Revvity (formerly PerkinElmer) is listed as an others. Broad incumbents are Corning Life Sciences and BICO (CELLINK). Lena Biosciences is listed as an emerging player.
Does Inventia Life Science have an API?
No public API is recorded for Inventia Life Science.
What industry is Inventia Life Science in?
Inventia Life Science's product category is 3D Bioprinting Instruments. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 3841.